Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)

<p>The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity&nbsp;(NOFO)&nbsp;to&nbsp;solicit applications that propose early to definitive clinical trials. Trials testing drugs, devices, biologics, procedures, behavioral, social, economic, health services, or other biomedical or non-pharmacological interventions are of interest to this initiative. The trials should align with the research mission of the participating Institutes, Centers, and Offices (ICOs) of the NIH.&nbsp;</p><p>The&nbsp;NOFO will&nbsp;utilize&nbsp;the R61/R33 activity code, a bi-phasic, milestone-driven award. The R61 phase provides support for planning activities, and the R33 phase provides support for a clinical trial, with a maximum project period of 7 years. &nbsp;</p><p>Applications are not being&nbsp;solicited&nbsp;at this time.&nbsp;This notice&nbsp;is being provided to allow potential applicants sufficient time to develop meaningful collaborations and relevant projects.&nbsp;Investigators with&nbsp;expertise&nbsp;in clinical trial planning,&nbsp;design,&nbsp;implementation, intervention development, and/or stakeholder engagement&nbsp;are encouraged to consider applying for the NOFO.&nbsp;</p>